Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). - Wikidata - awgldk - TriplyDB

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

http://www.wikidata.org/entity/Q33444047

about

Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials Immunotoxicity of 2',3'-dideoxyinosine in female B6C3F1 mice Pathogenesis of human immunodeficiency virus infection The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction Inhibition of HIV-reverse transcriptase activity by some phloroglucinol derivatives Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1 Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucl Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compounds Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design PMTI, a broadly active unusual single-stranded polyribonucleotide, inhibits human immunodeficiency virus replication by multiple mechanisms Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.Combinatorial approaches to the prevention and treatment of HIV-1 infection Mutagenesis of key residues identifies the connection subdomain of HIV-1 reverse transcriptase as the site of inhibition by heme.

P2860

Q21562140-E3D072B6-7B62-434D-A900-A8D60DDD2997 Q23915942-FD86DDE3-8873-47A9-9CE5-29A81040BC4F Q24634681-ED6FA6BD-CF53-4122-AD02-67586422D93A Q24655011-78F331A6-375D-42A1-B43E-96D862748757 Q28316326-1B8BF913-C6C2-4103-BE45-9465EC35ED3C Q28318476-5639E4C1-CB18-4B6A-8B91-B6ACE3885CA8 Q28319933-9CAE8C1F-D1A1-4F9A-807A-F285E68F10CF Q28320896-31B6FF8C-B44E-4547-ABC8-039C74178F3B Q28323307-688C9600-D18A-4925-89E8-35D02AB71DA1 Q28323972-D9EB8D79-60F9-42FC-BC86-3321CE702042 Q28323983-5DA44DEC-54FA-4D9C-B78D-800C7267A317 Q28326720-F56BD62A-3298-48EA-AC8E-1A138C5DDEF3 Q28332188-ABFA0728-8F81-4CE8-8E80-DA58D03FCEAF Q28333679-87C709B1-A4C2-43FD-BB8F-DB6874940139 Q28334680-8689D383-0CFA-4EFA-BD32-030891487965 Q28335926-87E5955D-CB7D-4608-A7E7-2E82C0446F66 Q28340356-6F60F672-8A38-4C74-82FF-083A590022EF Q28342189-30042666-8797-4495-BDAC-9AB707200917 Q28342341-85E47FA4-0293-42D7-A90C-783DE03DC2EB Q28342606-150AA2DC-A25D-481C-AB17-510CB03E7C5C Q28342653-0EA82815-7B33-409B-B323-6C45860313B1 Q28342825-6BBE8DF8-7A48-48E9-AE7C-86CE1988D684 Q28343184-6AFD6381-E562-4A01-A15E-835B24FB36DD Q28359652-E19DD4BD-BF1B-4CF5-B541-D7A8A95067AD Q28359853-18CD80B3-A244-49A1-BDCD-FC575F1698B3 Q28360109-9C3F1E45-9F4C-4C90-8478-EE4D925E2601 Q28367493-F741E115-15A6-4964-BC3F-C25A064A49C0 Q28367543-B6FC912C-572A-4954-A0E4-956DCF01F214 Q28367642-C21143AC-518E-4826-A923-BBF980D3614C Q28368058-00D3F06D-A2C5-48A0-A172-5980466EE4DA Q28369082-C5F5C2B0-3E8A-49A5-934B-1D3CE95A8242 Q28369111-F737CBEC-4101-4EB3-9CA5-61039CD24CB9 Q28369425-921490F6-2ADB-41E6-BBA1-7341EFC877BE Q28371767-B7CDD3D3-794F-4F89-8C34-B8E492D54F6D Q28378322-DF202A7D-DD3F-45BC-B00E-40433A7A4CEB Q28378796-29D4468B-508C-4871-904E-F473C64D2AE8 Q28379270-361E3D0E-93B6-4D3C-8F81-221FFEDED280 Q28379316-376F7C0D-0757-47CD-9F9D-D83414B25206 Q30400060-31FF3139-B5D1-4CBD-8798-DC0137DDD67A Q30658869-D1F605BD-BD32-4B00-838D-BD2F38E81B13

P2860

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

http://www.wikidata.org/entity/Q33444047

description

1988 nî lūn-bûn

@nan

1988 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1988 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1988年の論文

@ja

1988年論文

@yue

1988年論文

@zh-hant

1988年論文

@zh-hk

1988年論文

@zh-mo

1988年論文

@zh-tw

1988年论文

@wuu

name

Phase I studies of 2',3'-dideo ...... rnating with zidovudine (AZT).

@ast

Phase I studies of 2',3'-dideo ...... rnating with zidovudine (AZT).

@en

type

label

Phase I studies of 2',3'-dideo ...... rnating with zidovudine (AZT).

@ast

Phase I studies of 2',3'-dideo ...... rnating with zidovudine (AZT).

@en

prefLabel

Phase I studies of 2',3'-dideo ...... rnating with zidovudine (AZT).

@ast

Phase I studies of 2',3'-dideo ...... rnating with zidovudine (AZT).

@en

P1433

Q33444047-3C814EF7-5982-44BD-8AE3-8B3FF80DF8E7

P1476

Q33444047-AD041A4B-5F4D-437B-85A0-62139D402E3B

P2093

Q33444047-2162D6E2-1B45-48BD-848D-990ACB6515E6

Q33444047-256F01ED-1B64-4BF3-8FAC-A6657F4F1E62

Q33444047-2E08B89C-4067-4E25-989F-CB966BB9BC7B

Q33444047-3B701B66-0115-4C81-BE9B-65A281F42E9F

Q33444047-4AE84C0E-821B-4170-805B-47D198C271BB

Q33444047-57F62C7B-6973-43C9-9753-93838D162875

Q33444047-596AA59B-C5FC-4ACD-9AB7-04D795233473

Q33444047-6B28CE46-2DF9-463A-A0AC-C0AEA290C980

Q33444047-AE6E5FAD-3E63-4D06-AAC7-9C8521FB1EBD

Q33444047-E53A007A-39EC-4D04-A97B-B071DE5DDAF9

P304

Q33444047-A252C3F9-843C-498A-88D2-91AA8888F14A

P31

Q33444047-A25E0E15-BD66-4590-9EC0-8297C31590C5

P356

Q33444047-D57CD941-5575-450C-8D57-B6BA0ACF223E

P407

Q33444047-762B3F3E-18B7-4D0A-AB70-55AE0CCD9EB3

P433

Q33444047-91DE87D4-B4DB-4333-8EB1-3B9BED027248

P478

Q33444047-6646E4DB-8EF3-4B36-9B00-456F92CFF6A2

P577

Q33444047-0EAD08F8-7B88-4EDD-B92F-CEBE31C7AB69

P698

Q33444047-B9022F96-2F8B-4F55-A3B3-40D9A5CD1620

P356

S0140-6736(88)90283-8

P1433

P1476

Phase I studies of 2',3'-dideo ...... rnating with zidovudine (AZT).

@en

P2093

C F Perno

http://www.w3.org/2001/XMLSchema#string

J P Allain

http://www.w3.org/2001/XMLSchema#string

M A Fischl

http://www.w3.org/2001/XMLSchema#string

M C McNeely

http://www.w3.org/2001/XMLSchema#string

N McAtee

http://www.w3.org/2001/XMLSchema#string

R Dubinsky

http://www.w3.org/2001/XMLSchema#string

R J Wills

http://www.w3.org/2001/XMLSchema#string

R V Thomas

http://www.w3.org/2001/XMLSchema#string

R W Klecker

http://www.w3.org/2001/XMLSchema#string

R Yarchoan

http://www.w3.org/2001/XMLSchema#string

P304

76-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(88)90283-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

8577

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

1988-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

2891981

http://www.w3.org/2001/XMLSchema#string